Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: A clinical and neurophysiological study

Amyotrophic Lateral Sclerosis

Volumn 11, Issue 4, 2010, Pages 359-363

  Gilio, Francesca ^c   Iacovelli, Elisa ^a   Frasca, Vittorio ^a   Gabriele, Maria ^a   Giacomelli, Elena ^a   Picchiori, Floriana ^a   Soldo, Pietro ^a   Cipriani, Anna Maria ^c   Ruoppolo, Giovanni ^a   Inghilleri, Maurizio ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SANDRO PERTINI HOSPITAL   (Italy)

Author keywords

Amyotrophic lateral sclerosis; Botulinum toxin type A; Sialorrhoea

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ACTION POTENTIAL; ADULT; AGED; AMPLITUDE MODULATION; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BULBAR PARALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; FEMALE; HUMAN; HYPERSALIVATION; MALE; MASSETER MUSCLE; MASTICATORY MUSCLE; NEUROPHYSIOLOGY; OPEN STUDY; ORBICULARIS OCULI MUSCLE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; XEROSTOMIA; CASE CONTROL STUDY; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; ELECTROMYOGRAPHY; EVOKED MUSCLE RESPONSE; MIDDLE AGED; PAIN MEASUREMENT; PAROTID GLAND; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SIALORRHEA; SKELETAL MUSCLE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BOTULINUM TOXINS, TYPE A; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; PAROTID GLAND; PROSPECTIVE STUDIES; SIALORRHEA;

EID: 77953787713     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960903264998     Document Type: Article

References (36)

1. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000; 69: 121-123
2. Cummings CW, F rederickson JM, H arker LA, K rause CK, Schuller DE, Richardson MA, editors. Otolaryngology head and neck surgery, physiology. 3rd edn. St. Louis : Mosby- Year Book Inc.; 1998. pp. 1219.
3. Baltadzhieva R, G urevich , K orczyn AD. A utonomic impairment in amyotrophic lateral sclerosis. Curr Opin Neurol. 2005; 18: 487-493
4. Johnson H, S cott A. S aliva management. In: Cichero J, Murdoch B, editors. Dysphagia: Foundations, Theory and Practice; Wiley & Sons Ltd, Chichester 2006. pp. 126- 45 .
5. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. An evidence based review with good practice points. Eur J Neurol. 2005; 12: 921-938
6. Lew KM, Y ounis RT, L azar RH. T he current management of sialorrhoea. Ear Nose Throat J. 1991; 70: 99-105.
7. Naumann M, J ost WH, T oyka KV. B otulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol. 1999; 56: 914-916
8. Blasi J, C hapman ER, L ink E, B inz T, Y amasaki S, de Camilli P, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993; 365: 160-163
9. Naumann M, Flachenecker P, Bröcker EB, T oyka KV, Reiners K. Botulinum toxin for palmar hyperhydrosis. Lancet. 1997; 349: 252 .
10. Bushara KO. S ialorrhoea in amyotrophic lateral sclerosis: a hypothesis of a new treatment - botulinum toxin A injections of the parotid glands. Med Hypotheses. 1997; 48: 337-339
11. Meningaud JP, P itak-Arnnop P, Chikhani L, B ertrand JC. Drooling of saliva: a review of the aetiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006; 101: 48-57.
12. Bhatia KP, Munchau A, Brown P. Botulinum toxin is a useful treatment in excessive drooling in saliva. J Neurol Neurosurg Psychiatry. 1999; 67: 697.
13. Porta M, Gamba M, Bertacchi G, Vaj P. T reatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders. J Neurol Neurosurg Psychiatry. 2001; 70: 538-540
14. Winterholler MG, Erbguth FJ, W olf S, K at S. B otulinum toxin for the treatment of sialorrhoea in ALS: serious side-effects of a transductal approach. J Neurol Neurosurg Psychiatry. 2001; 70: 417-418
15. Tan EK, L o YL, S eah A, A uchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci. 2001; 190: 95-97
16. Lipp A, T rottenberg T, S chink T, K upsch A, A rnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003; 61: 1279-1281
17. Meijer JW, van Kuijk AA, Geurts AC,S chelhaas HJ, Z warts MJ. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2008; 87: 321-324
18. Brooks BR, Miller RG, Swash M, M unsat TL and World Federation of Neurology Research Group on Motor Neuron Diseases . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1: 293-299
19. ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996; 53: 141-147
20. White KS, S her KJ. S aliva: a review and experimental investigation of major techniques. Psychophysiology. 1977; 14: 203-212
21. Montecucco C, S chiavo G. Tetanus and botulism neurot oxins: a new group of zinc proteases. Trend Bio Sci. 1993; 18: 324-327
22. Verma A, Steele J. Botulinum toxin improves sialorrhoea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve. 2006; 34: 235-237
23. Ondo WG, Hunter C, M oore W. A double-blind placebocontrolled trial of botulinum toxin B for sialorrhoea in Parkinson's disease. Neurology. 2004; 62: 37-40.
24. Costa J, R ocha ML, F erreira J, E vangelista T, C oelho M, de Carvalho M. Botulinum toxin type B improves sialorrhoea and quality of life in bulbar onset amyotrophic lateral sclerosis. J Neurol. 2008; 255: 545-550
25. Charchaflie RJ, B ustos Fernandez L, P erec CJ, G onzalez E, Marzi A. Functional studies of the parotid and pancreas glands in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 1974; 37: 863-867 .
26. Schneyer LH. M ethod for the collection of separate submaxillary and sublingual saliva in man. J Dent Res. 1955; 34: 257-261
27. Enfors BO. T he parotid and submandibular secretion in man. Quantitative recordings of the normal and pathological activity. Acta Otolaryngol Suppl. 1962; 172: 1-67.
28. Manrique D. Application of botulinum toxin to reduce saliva in patients with amyotrophic lateral sclerosis. Braz J Otorhinolaryngol. 2005; 71: 566-569
29. Contarino MF, Pompili M, Tittoto P, Vanacore N, Sabatelli M, Cedrone A, et al. Botulinum toxin B ultrasoundguided injections for sialorrhoea in amyotrophic lateral sclerosis and Parkinson's disease. Parkinsonism Relat Disord. 2007; 13: 299-303.
30. Suskind DL, T ilton A. C linical study of botulinum A toxin in the treatment of sialorrhoea in children with cerebral palsy. Laryngoscope. 2002; 112: 73-81.
31. Ellies M, G ottstein U, R ohrbach-Volland S, A rglebe C, Laskawi R. Reduction of salivary flow with botulinum toxin: extended report on 33 patients with drooling, salivary fistulas, and sialadenitis. Laryngoscope. 2004; 114: 1856-1860
32. Nóbrega AC, R odrigues B, T orres AC, E nzo A, M elo A. Does botulinum toxin decrease frequency and severity of sialorrhoea in Parkinson's disease?. J Neurol Sci. 2007; 253: 85-87
33. Lange DJ, R ubin M, Greene PE, K ang UJ, M oskowitz CB, Brin MF, et al. Distant effects of locally injected botulinum toxin: a double-blind study of single fibre EMG changes. Muscle Nerve. 1991; 14: 672-675
34. Garner CG, S traube A, W itt TN, G asser T, O ertel WH. Time-course of distant effects of local injections of botulinum toxin. Mov Disord. 1993; 8: 33-37
35. Eleopra R, T ugnoli V, Caniatti L, G asser T, de Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology. 1996; 46: 1158-1160
36. Lorenzano C, B agnato S, Gilio F, F abbrini G, Berardelli A. No clinical or neurophysiological evidence of botulinum toxin diffusion to non-injected muscles in patients with hemifacial spasm. Neurotox Res. 2006; 9: 141-144